HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance

Nature Communications

Volumn 5, Issue , 2014, Pages

  Chuang, Huai Chia ^a   Sheu, Wayne H H ^b,c   Lin, Yi Ting ^a   Tsai, Ching Yi ^a   Yang, Chia Yu ^a   Cheng, Yu Jhen ^a   Huang, Pau Yi ^a   Li, Ju Pi ^a   Chiu, Li Li ^b   Wang, Xiaohong ^d   Xie, Min ^e   Schneider, Michael D ^f   Tan, Tse Hua ^a,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INTERLEUKIN 6; LEPTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; CD3 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; MAP4K4 PROTEIN, HUMAN; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

FAT; HORMONE; IMMUNE SYSTEM; METABOLISM; RODENT;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLISM; MOLECULAR STABILITY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; TH17 CELL; UPREGULATION; 3T3 CELL LINE; ANIMAL; CD4+ T LYMPHOCYTE; CYTOLOGY; EXON; FIBROBLAST; GENETICS; GLUCOSE TOLERANCE TEST; HEK293 CELL LINE; JURKAT CELL LINE; KNOCKOUT MOUSE; LYMPHOCYTE; LYSOSOME; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

3T3 CELLS; 3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; EXONS; FIBROBLASTS; GLUCOSE TOLERANCE TEST; HEK293 CELLS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LYMPHOCYTES; LYSOSOMES; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; TH17 CELLS; TNF RECEPTOR-ASSOCIATED FACTOR 2;

EID: 84907322144     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5602     Document Type: Article

References (58)

1. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517 (2009).
2. Muranski, P. & Restifo, N. P. Essentials of Th17 cell commitment and plasticity. Blood 121, 2402-2414 (2013).
3. Singh, S. P., Zhang, H. H., Foley, J. F., Hedrick, M. N. & Farber, J. M. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J. Immunol. 180, 214-221 (2008).
4. + regulatory T cells. J. Immunol. 180, 122-129 (2008).
5. Weaver, C. T., Elson, C. O., Fouser, L. A. & Kolls, J. K. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu. Rev. Pathol. 8, 477-512 (2013).
6. Tesmer, L. A., Lundy, S. K., Sarkar, S. & Fox, D. A. Th17 cells in human disease. Immunol. Rev. 223, 87-113 (2008). (Pubitemid 351986173)
7. Jagannathan-Bogdan, M. et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 186, 1162-1172 (2011).
8. Yao, Z. et al. A novel human STE20-related protein kinase, HGK, that specifically activates the c-Jun N-terminal kinase signaling pathway. J. Biol. Chem. 274, 2118-2125 (1999).
9. Xue, Y. et al. Mesodermal patterning defect in mice lacking the Ste20 NCK interacting kinase (NIK). Development 128, 1559-1572 (2001). (Pubitemid 32514840)
10. Danai, L. V. et al. MAP4K4 suppresses Srebp-1 and adipocyte lipogenesis independent of JNK signaling. J. Lipid Res. 54, 2697-2707 (2013).
11. Tang, X. et al. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport. Proc. Natl Acad. Sci. USA 103, 2087-2092 (2006). (Pubitemid 43271627)
12. Bouzakri, K. & Zierath, J. R. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-α-induced insulin resistance. J. Biol. Chem. 282, 7783-7789 (2007). (Pubitemid 47093599)
13. Bouzakri, K., Ribaux, P. & Halban, P. A. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects β cells from tumor necrosis factor-a-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. J. Biol. Chem. 284, 27892-27898 (2009).
14. Aouadi, M. et al. Orally delivered siRNA targeting macrophage MAP4K4 suppresses systemic inflammation. Nature 458, 1180-1184 (2009).
15. Collins, C. S. et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl Acad. Sci. USA 103, 3775-3780 (2006). (Pubitemid 43376631)
16. Liang, J. J. et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin. Cancer Res. 14, 7043-7049 (2008).
17. Hao, J. M. et al. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J. Pathol. 220, 475-489 (2010).
18. Qiu, M. H. et al. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol. Res. Pract. 208, 541-548 (2012).
19. Loftus, J. C. et al. A novel interaction between Pyk2 and MAP4K4 is integrated with glioma cell migration. J. Signal Transduct. 2013, 956580 (2013).
20. Hu, M. C., Qiu, W. R., Wang, X., Meyer, C. F. & Tan, T. H. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 10, 2251-2264 (1996). (Pubitemid 26322362)
21. Diener, K. et al. Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc. Natl Acad. Sci. USA 94, 9687-9692 (1997). (Pubitemid 27408124)
22. Shui, J. W. et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses. Nat. Immunol. 8, 84-91 (2007).
23. Chuang, H. C. et al. The kinase GLK controls autoimmunity and NF-κB signaling by activating the kinase PKC-θ in T cells. Nat. Immunol. 12, 1113-1118 (2011).
24. Liu, H., Su, Y. C., Becker, E., Treisman, J. & Skolnik, E. Y. A Drosophila TNF-receptor-associated factor (TRAF) binds the Ste20 kinase Misshapen and activates Jun kinase. Curr. Biol. 9, 101-104 (1999). (Pubitemid 29083536)
25. Takeuchi, M., Rothe, M. & Goeddel, D. V. Anatomy of TRAF2. Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins. J. Biol. Chem. 271, 19935-19942 (1996).
26. Walsh, M. C., Kim, G. K., Maurizio, P. L., Molnar, E. E. & Choi, Y. TRAF6 autoubiquitination-independent activation of the NFκB and MAPK pathways in response to IL-1 and RANKL. PLoS ONE 3, e4064 (2008).
27. Bastard, J. P. et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 87, 2084-2089 (2002).
28. Chakrabarti, P. & Kandror, K. V. Adipose triglyceride lipase: a new target in the regulation of lipolysis by insulin. Curr. Diabetes. Rev. 7, 270-277 (2011).
29. Morino, K. et al. Muscle-specific IRS-1 Ser->Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes 57, 2644-2651 (2008).
30. Copps, K. D. et al. Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab. 11, 84-92 (2010).
31. + T cells in TallyHo/JngJ mice. PLoS One 6, e18168 (2011).
32. Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-1271 (1995). (Pubitemid 26007816)
33. Procaccini, C. et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33, 929-941 (2010).
34. Vince, J. E. et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182, 171-184 (2008). (Pubitemid 352008630)
35. Li, L., Soetandyo, N., Wang, Q. & Ye, Y. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793, 346-353 (2009).
36. Senn, J. J., Klover, P. J., Nowak, I. A. & Mooney, R. A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399 (2002). (Pubitemid 35403441)
37. Rotter, V., Nagaev, I. & Smith, U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278, 45777-45784 (2003). (Pubitemid 37432722)
38. Lagathu, C. et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem. Biophys. Res. Commun. 311, 372-379 (2003). (Pubitemid 37340087)
39. Kim, H. J. et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067 (2004).
40. Nieto-Vazquez, I., Fernandez-Veledo, S., de Alvaro, C. & Lorenzo, M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57, 3211-3221 (2008).
41. Glund, S. & Krook, A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Phys. 192, 37-48 (2008). (Pubitemid 350265360)
42. Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481-1489 (2011).
43. Klover, P. J., Clementi, A. H. & Mooney, R. A. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146, 3417-3427 (2005). (Pubitemid 41058114)
44. Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75-79 (2002). (Pubitemid 34101732)
45. Matthews, V. B. et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53, 2431-2441 (2010).
46. Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
47. Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423-430 (2014).
48. Sadagurski, M. et al. Human IL6 enhances leptin action in mice. Diabetologia 53, 525-535 (2010).
49. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183-190 (2005). (Pubitemid 40321354)
50. Franckhauser, S. et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51, 1306-1316 (2008).
51. Zuniga, L. A. et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J. Immunol. 185, 6947-6959 (2010).
52. Trujillo, M. E. et al. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J. Clin. Endocrinol. Metab. 89, 5577-5582 (2004). (Pubitemid 39518443)
53. + T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J. Immunol. 185, 7474-7479 (2010).
54. + T cells promotes Th17 responses in systemic lupus erythematosus. J. Immunol. 190, 3054-3058 (2013).
55. Sartorius, T. et al. Association of common genetic variants in the MAP4K4 locus with prediabetic traits in humans. PLoS ONE 7, e47647 (2012).
56. Cohen, P. et al. Selective deletion of leptin receptor in neurons leads to obesity. J. Clin. Invest. 108, 1113-1121 (2001). (Pubitemid 32995369)
57. Kucharzik, T., Hudson, 3rd J. T., Waikel, R. L., Martin, W. D. & Williams, I. R. CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: demonstration using a CCR6 EGFP knock-in mouse. Eur. J. Immunol. 32, 104-112 (2002). (Pubitemid 34092827)
58. Eglen, R. M. et al. The use of Alpha Screen technology in HTS: current status. Curr. Chem. Genomics 1, 2-10 (2008).